Key result
Oral administration of doxorubicin in rats resulted in approximately 1% bioavailability, primarily due to limited paracellular intestinal absorption rather than first-pass metabolism or efflux.
Why the study?
Does limited intestinal absorption via the paracellular pathway explain the low oral bioavailability of doxorubicin in rats and Caco-2 cells?
Does limited intestinal absorption via the paracellular pathway explain the low oral bioavailability of doxorubicin in rats and Caco-2 cells?
The low oral bioavailability of doxorubicin is primarily driven by limited intestinal absorption via the paracellular pathway rather than first-pass metabolism or efflux pumps.
Answers are grounded in this paper and cite their sources.
Should not alter clinical doxorubicin use; extends preclinical absorption insights but remains hypothesis-generating for human translation.
Doxorubicin exhibited dose-independent pharmacokinetics after intravenous (5-20 mg/kg) and oral (20-100 mg/kg) administration to rats. Nearly all (82.1-99.7%) of the orally administered doxorubicin remained unabsorbed, and the hepatic first-pass extraction ratio and oral bioavailability of doxorubicin were approximately 0.5% and 1%, respectively. Based on these results, it is likely that the primary factor responsible for the low oral bioavailability of doxorubicin is the limited intestinal absorption, rather than the CYP3A4-mediated first-pass metabolism. 2. Moreover, the in vitro transport and cellular uptake studies using Caco-2 cell monolayers have revealed that doxorubicin crosses the intestinal epithelium primarily via the paracellular pathway (accounting for 85.6% of the overall absorptive transport) probably due to its physicochemical properties (hydrophilic cation; pKa = 9.67, log P = -0.5). These results suggest that P-glycoprotein (P-gp)-mediated efflux activity does not play a significant role in limiting the intestinal absorption of doxorubicin, attenuating the absorptive transport by only 5.56-13.2%. 3. Taken together, the present study demonstrated that the limited and paracellular intestinal absorption of doxorubicin was a major factor responsible for its low oral bioavailability, restricting the role of CYP3A4-mediated first-pass metabolism and P-gp-mediated efflux.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2012) studied this question. Doxorubicin was evaluated on Oral bioavailability and intestinal absorption. Oral administration of doxorubicin in rats resulted in approximately 1% bioavailability, primarily due to limited paracellular intestinal absorption rather than first-pass metabolism or efflux.
Synapse has enriched 10 related papers. Consider them for comparative context: